MarketCap
Facebook
X
TelegramGeschäftsbericht 2022
hinzugefügt 21.12.2024
Celyad Oncology SA Kurshistorie 2011-2026 | CYAD
Kurshistorie Jährlich Celyad Oncology SA
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.47 | 2.67 | 7.63 | 8.39 | 20.9 | 39.5 | 22.1 | 41.1 | - | - | - | - |
Alle Zahlen in EUR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 41.1 | 0.47 | 17.8 |
Kurshistorie anderer Aktien in der Pharmaeinzelhändler
| Name | Kurshistorie | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
18.2 | - | 2.43 % | $ 254 M |  Germany |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
133 | $ 9.85 | 2.66 % | $ 637 M |  USA |
 |
AgeX Therapeutics
AGE
|
13 | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
0.68 | - | - | $ 866 M |  China |
 |
Akero Therapeutics
AKRO
|
48.4 | - | - | $ 3.67 B | USA |
 |
Burford Capital Limited
BUR
|
10.6 | $ 5.12 | 3.75 % | $ 820 M |  Britain |
 |
Midatech Pharma plc
MTP
|
0.29 | - | -18.52 % | $ 27.3 M | Britain |
 |
AlloVir
ALVR
|
9.78 | - | 4.14 % | $ 49.1 M | USA |
 |
BioNTech SE
BNTX
|
91.2 | $ 98.05 | -5.22 % | $ 27.2 B | Germany |
 |
Biophytis SA
BPTS
|
0.33 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
3.36 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
19.3 | $ 21.95 | -2.23 % | $ 3.64 B | USA |
 |
Athira Pharma
ATHA
|
0.42 | - | - | $ 269 M | USA |
 |
Applied Molecular Transport
AMTI
|
0.57 | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
0.5 | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
74.2 | - | - | $ 96.9 B | Britain |
 |
Cerus Corporation
CERS
|
2.6 | $ 2.57 | 26.59 % | $ 490 M | USA |
 |
Atreca
BCEL
|
1.27 | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
1.7 | - | -7.31 % | $ 87 M | USA |
 |
Calithera Biosciences
CALA
|
13.3 | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
0.31 | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
32.3 | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
26.9 | - | - | $ 3.74 B | USA |
 |
Caladrius Biosciences
CLBS
|
0.43 | - | -16.75 % | $ 25.8 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
2.44 | - | - | $ 231 M | USA |
 |
Cardiff Oncology
CRDF
|
1.74 | $ 1.72 | -0.87 % | $ 115 M | USA |
 |
Aeterna Zentaris
AEZS
|
5.72 | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
1.26 | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
12 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.3 | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
14.1 | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
3.17 | - | 1.93 % | $ 17.4 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
13.3 | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
5.34 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
1.31 | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.92 | $ 2.91 | -8.78 % | $ 4.79 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
2.11 | - | -9.21 % | $ 2.55 M | USA |
 |
Editas Medicine
EDIT
|
2.32 | $ 2.9 | -3.27 % | $ 257 M | USA |
 |
Edesa Biotech
EDSA
|
1.9 | $ 18.92 | 3.53 % | $ 60.5 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
2.84 | - | -5.68 % | $ 8.28 M | USA |
 |
CureVac N.V.
CVAC
|
19.3 | - | - | $ 867 M | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
0.82 | - | -11.43 % | $ 502 K | USA |
 |
Applied Therapeutics
APLT
|
6.42 | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
3.32 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
0.14 | - | -39.0 % | $ 4.57 M | USA |
 |
Evogene Ltd.
EVGN
|
0.81 | $ 0.78 | - | $ 27.9 M | Israel |
 |
Aravive
ARAV
|
1.66 | - | -13.39 % | $ 1.45 M | USA |